Corporate profile

Home > Corporate profile

Corporate profile

Overview

Company nameTMRC Co., Ltd.
Location of head officeMI Bldg.,
1-12-12, KitaShinjuku, Shinjuku-ku, Tokyo 169-0074, JAPAN  <Map>
Board Directors
Naoki TaniPresident and CEO
EstablishedJanuary 2002
Total Fund Raised2,957,880,000 yen (as of December 31, 2013)

page top

History

2002JanuaryEstablished in Minato-ku, Tokyo, as a Contract Research Organization (CRO) specializing in the field of cancer.
2004FebruaryObtained a license for Tamibarotene, and started an R&D business.
2005FebruaryTM-411 for the treatment of multiple myeloma was designated as a supported project by the Pharmaceuticals and Medical Devices Agency (the present National Institute of Biomedical Innovation).
2006DecemberGranted a license for Tamibarotene, for the treatment of acute promyelocytic leukemia (APL), to a US company Innovive Pharmaceuticals, Inc.in North American territory.
2007AugustGranted a license for Tamibarotene, for the treatment of hepatocellular carcinoma (HCC), to a Japanese company Zeria Pharmaceutical Co., Ltd. in Japanese territory.
 September

Granted a license for Tamibarotene, for the treatment of acute promyelocytic leukemia (APL), to Innovive Pharmaceuticals, Inc. in European territory.

 November

Started a pivotal Phase II clinical trial of Tamibarotene for the treatment of acute promyelocytic leukemia (APL) in the U.S.A. and Europe.

  Granted a license for Tamibarotene, for the treatment of acute promyelocytic leukemia (APL), to a Japanese company LOTUS PHARMACEUTICAL CO.,LTD.(former Oder-Made Souyaku Co., Ltd.) in Chinese territory.
2008AugustStarted a Phase I/II clinical trials of Tamibarotene for the treatment of hepatocellular carcinoma (HCC) in Japan.
2009MarchSpun off CRO business and established it as a subsidiary company, then transferred 100% of stocks to Sugi Medical Co., Ltd.
2011FebruaryStarted a pivotal Phase II/III clinical trial of Tamibarotene for the treatment of acute promyelocytic leukemia (APL) in China.
 MarchGranted a license by FRR for Tamibarotene, for the treatment of Non-small-cell lung cancer (NSCLC),to a US company CytRx Corporation in North American territory.
  Started a Phase IIb clinical trial of Tamibarotene for the treatment of Non-small-cell lung cancer (NSCLC) in U.S.A.
2014JuneGranted a license for Tamibarotene, for the treatment of Pediatric cancer, to a Japanese company Ohara Pharmaceutical Co., Ltd. in Japanese territory.
 JulyReached an agreement with Children's Hospital Los Angeles (CHLA *) to develop and commercialize TM-411 in neutropenia.
2015SeptemberGranted a license for Tamibarotene, for the treatment of cancer, to a US company Syros Pharmaceuticals Inc., in North American and European territory.

*Children's Hospital Los Angeles has been named the best children's hospital on the West Coast and among the top five in the nation for clinical excellence with its selection to the prestigious U.S. News & World Report Honor Roll. Children's Hospital is home to The Saban Research Institute, one of the largest and most productive pediatric research facilities in the United States. Children's Hospital is also one of America's premier teaching hospitals through its affiliation since 1932 with the Keck School of Medicine of the University of Southern California.

page top

Board Directors

under construction

page top

Management Team

under construction

page top